Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2508 Target Snapshot

Cyclin-dependent kinase 6 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,685Compounds
195Assays
9Approved Drugs
1,298.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Cyclin-dependent kinase 6 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q00534. Start with breast cancer, then reuse UniProt Q00534 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt Q00534 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
breast cancer

Cyclin-dependent kinase 6 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB, RIBOCICLIB SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 6 as ChEMBL target CHEMBL2508, mapped to UniProt Q00534. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2508
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00534
Cyclin-dependent kinase 6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 6 is the right protein anchor across sources, using UniProt Q00534 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCyclin-dependent kinase 6
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ00534
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 6
UniProt AccessionQ00534
Component TypeProtein
Sequence Length326 aa

Cyclin-dependent kinase 6

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 6, mapped to UniProt Q00534. Sequence length is 326 aa.

Mapped IDQ00534
Review nameCyclin-dependent kinase 6
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Cyclin-dependent kinase 6 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
6 linked drugs · 6 direct · 6 efficacy
Linked drugABEMACICLIB
Linked drugALVOCIDIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Approved-linked Approved
neoplasm
5 linked drugs · 5 direct · 5 efficacy
Linked drugABEMACICLIB
Linked drugALVOCIDIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Approved-linked Approved
breast neoplasm
4 linked drugs · 4 direct · 4 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Linked drugTRILACICLIB
Approved-linked Approved
breast carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Approved-linked Approved
small cell lung carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugTRILACICLIB
Linked drugTRILACICLIB DIHYDROCHLORIDE
Linked drugUCN-01
Approved-linked Approved
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB, RIBOCICLIB SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
7
Phase III
14
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC501,046.0
KI4.0
KD248.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5762122 10.0 IC50 0.1 Preclinical
CHEMBL4446357 9.8 Ki 0.16 Clinical
CHEMBL5751717 9.7 IC50 0.2 Preclinical
CHEMBL5280928 9.7 Ki 0.2 Preclinical
CHEMBL5653589 9.53 Kd 0.296 Preclinical
CHEMBL5882717 9.52 IC50 0.3 Preclinical
CHEMBL3698653 9.44 IC50 0.36 Preclinical
CHEMBL3698657 9.39 IC50 0.41 Preclinical
CHEMBL5892046 9.22 IC50 0.6 Preclinical
CHEMBL3698681 9.12 IC50 0.75 Preclinical
Distribution

pChEMBL Value Distribution

13
5.0
21
5.5
44
6.0
87
6.5
123
7.0
220
7.5
257
8.0
174
8.5
14
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Properties Compare Identifier
RIBOCICLIB
CHEMBL3545110
Approved 2017
Properties Compare Identifier
PALBOCICLIB
CHEMBL189963
Approved 2015
Properties Compare Identifier
DABRAFENIB
CHEMBL2028663
Approved 2013
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
Assay Landscape

Assay Landscape

195
Total Assays
772
Tested Compounds
2
Assay Types
Binding — 171 assays, 772 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 133 729 7.8
cell-based format 26 24 7.5
subcellular format 10 18 6.2
assay format 2 1 5.1
Functional — 24 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 23 1 6.7
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine